Ironwood Pharmaceuticals IRWD Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ironwood Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ironwood Pharmaceuticals's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ironwood Pharmaceuticals's royalty — revenue?
- Ironwood Pharmaceuticals (IRWD) reported royalty — revenue of $800K in Q1 2026.
- How has Ironwood Pharmaceuticals's royalty — revenue changed year-over-year?
- Ironwood Pharmaceuticals's royalty — revenue decreased by 0.0% year-over-year, from $800K to $800K.
- What does royalty — revenue mean?
- This metric represents the gross revenue recognized from royalty-based arrangements associated with specific pharmaceutical products or intellectual property licenses, excluding any assessed taxes. It reflects the income generated through contractual rights to receive a percentage of sales or other performance-based payments from partners or licensees. Monitoring this figure helps investors assess the recurring cash flow stability and the long-term commercial performance of the company's licensed therapeutic portfolio.